Clinical Trials | November 10, 2025
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Relmada expects to initiate its Phase 3 program in the first half of 2026
Relmada expects to initiate its Phase 3 program in the first half of 2026
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
Vijaya Hospital, Chennai adopted Dozee’s AI-based contactless continuous remotemonitoring and early warning system to enhance patient safety
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Rahul has spent almost 17 years at Boston Consulting Group (BCG) where he has led the Health Care & Life Sciences practice
Subscribe To Our Newsletter & Stay Updated
